Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kos Pharmaceuticals, Inc

Latest From Kos Pharmaceuticals, Inc

Quite A Range: Adamas Ponders $10,000-$30,000 Price Tag For Gocovri

The US FDA approved the extended-release amantadine for levodopa-induced dyskinesia in Parkinson's disease. Adamas will finalize its pricing and begin selling the product later this year.

Approvals Launches

Market & Industry Briefs

Brief summaries of recent medtech market and industry developments. This month we cover J&J's and Medtronic's moves in a-fib, Abbott's acquisition of AMO, Northstar Neuroscience's demise and Invatec's European launch of its drug-eluting balloon. Plus a snapshot of ambulatory surgery in the US.

Medical Device

Back to Nature: Prescription Dietary Supplements Cash in on Cholesterol R&D Setbacks

Between big-name statins going generic and high-profile blow-ups like torcetrapib, Cordaptive and Vytorin, cholesterol drug development has been tough going. Some drug companies think the next big thing in lipid management is something different altogether: prescription-grade supplements. It may be just the thing for a risk-averse FDA.

Strategy Clinical Trials

What's the Difference? Sepracor's Xopenex Hit Hard by Coverage Cut

Xopenex reimbursement is being slashed by Medicare. The message: CMS wants proof of differentiation before it will pay more for line extensions and new formulations. That means trouble ahead for a lot of other products.

Reimbursement Government Payers
See All

Company Information